CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2022 CAD ($)	Sep. 30, 2021 CAD ($)
Operating activities
Earnings	$ 4,047	$ 4,349
Adjustments to reconcile earnings to net cash provided by operating activities:
Depreciation and amortization	3,195	2,805
Deferred income tax expense	600	789
Unrealized derivative fair value loss, net	1,691	86
Income from equity investments	(1,537)	(1,187)
Distributions from equity investments	1,293	1,197
Impairment of equity investments	0	111
Gain on joint venture merger transaction	(1,076)	0
Other	6	(128)
Changes in operating assets and liabilities	(602)	(656)
Net cash provided by operating activities	7,617	7,366
Investing activities
Capital expenditures	(3,204)	(5,887)
Long-term investments and restricted long-term investments	(566)	(241)
Distributions from equity investments in excess of cumulative earnings	426	295
Additions to intangible assets	(131)	(185)
Acquisition	(295)	0
Proceeds from joint venture merger transaction	522	0
Proceeds from disposition	0	122
Affiliate loans, net	90	19
Other	0	30
Net cash used in investing activities	(3,158)	(5,907)
Financing activities
Net change in short-term borrowings	367	84
Net change in commercial paper and credit facility draws	386	(32)
Debenture and term note issues, net of issue costs	4,739	6,135
Debenture and term note repayments	(2,244)	(1,888)
Contributions from noncontrolling interests	10	13
Distributions to noncontrolling interests	(189)	(210)
Common shares issued	3	3
Common shares repurchased	(151)	0
Preference share dividends	(254)	(274)
Common share dividends	(5,226)	(5,074)
Redemption of preferred shares held by subsidiary	0	(115)
Redemption of preference shares	(1,003)	0
Other	(223)	(64)
Net cash used in financing activities	(3,785)	(1,422)
Effect of translation of foreign denominated cash and cash equivalents and restricted cash	63	(12)
Net change in cash and cash equivalents and restricted cash	737	25
Cash and cash equivalents and restricted cash at beginning of period	320	490
Cash and cash equivalents and restricted cash at end of period	$ 1,057	$ 515